Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and MyoScience, Inc., a privately held medical technology company, have announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira, as detailed in the press release below issued by the companies.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and MyoScience, Inc., a privately held medical technology company, have announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira, as detailed in the press release below issued by the companies. Under the terms of the agreement, Pacira will make an initial payment of $120 million. MyoScience shareholders will be eligible to receive up to an additional $100 million in contingent payments upon achievement of certain regulatory and commercial milestones. The transaction is expected to close in April 2019 subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Latham & Watkins LLP represents MyoScience in the transaction with a corporate team inclusive of New York/Orange County partner Charles Ruck and Boston partner Julie Scallen, and Orange County associates Brett Urig, Stephanie Isaia, Shannon Cheng, and Gregory Van Buiten. Advice has also been provided on tax matters by partner Grace Lee and associate Jessica Chen in San Francisco; on intellectual property matters by partner Judith Hasko and associate Jekkie Kim in Silicon Valley; on employee benefits matters by partner James Metz and associate Ashley Wagner in Silicon Valley; and on regulatory matters by partners Ben Haas in Washington, D.C. and Christoph Engeler in Hamburg, counsel Nicole Liffrig Molife in Washington, D.C. and Jennifer Yoo in San Francisco, and associates Barrett Tenbarge in Washington, D.C. and Heather Deixler in San Francisco.
